Prognostic significance of ER-to-PR difference in ER+/HER2- early breast cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The ER-to-PR difference (EPD) can predict prognosis in ER+/HER2- early breast cancer. EPD-high tumors indicate a poorer prognosis, identifying patients who may benefit from closer monitoring and tailored treatment strategies.
Area Of Science
- Oncology
- Molecular Biology
- Biostatistics
Background
- Estrogen receptor-positive/HER2-negative (ER+/HER2-) breast cancer is a prevalent subtype.
- Accurate prognostic markers are crucial for managing early-stage disease.
Purpose Of The Study
- To evaluate the prognostic value of the ER-to-PR difference (EPD) in ER+/HER2- early breast cancer (EBC).
- To identify a novel biomarker for stratifying patients with potentially poorer outcomes.
Main Methods
- Retrospective cohort study of 3,340 ER+/HER2- EBC patients.
- Optimal EPD cutoff determined using X-tile analysis (10%).
- Prognostic value assessed via Cox proportional hazards model and machine learning.
Main Results
- An EPD cutoff of 10% stratified patients into EPD-low and EPD-high groups.
- EPD-high tumors were associated with a poorer prognosis.
- EPD was an independent prognostic factor for disease-free survival (DFS) (HR: 1.496, P=0.004).
Conclusions
- EPD serves as a novel, independent prognostic marker in ER+/HER2- EBC.
- EPD aids in identifying patients with a poor prognosis.
- Integrating EPD into predictive models improves DFS prediction, supporting clinical decision-making.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
